NI201100191A - Combinación antitumoral que comprende ave8062 y sorafenib - Google Patents

Combinación antitumoral que comprende ave8062 y sorafenib

Info

Publication number
NI201100191A
NI201100191A NI201100191A NI201100191A NI201100191A NI 201100191 A NI201100191 A NI 201100191A NI 201100191 A NI201100191 A NI 201100191A NI 201100191 A NI201100191 A NI 201100191A NI 201100191 A NI201100191 A NI 201100191A
Authority
NI
Nicaragua
Prior art keywords
ave8062
sorafenib
combination including
antitumor
antitumor combination
Prior art date
Application number
NI201100191A
Other languages
English (en)
Inventor
Demers Brigitte
Vrignaud Patricia
Original Assignee
Aplicaciones Terapeuticas En El Dominio Cardiovascular De Derivados
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aplicaciones Terapeuticas En El Dominio Cardiovascular De Derivados filed Critical Aplicaciones Terapeuticas En El Dominio Cardiovascular De Derivados
Publication of NI201100191A publication Critical patent/NI201100191A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a una combinación farmacéutica antitumoral que comprende AVE8062 de fórmula (I) y sorafenib de fórmula (II), pudiendo estar estos dos agentes antitumorales en forma e base o en forma de una sal de un ácido farmacéuticamente aceptable.
NI201100191A 2009-05-07 2011-11-04 Combinación antitumoral que comprende ave8062 y sorafenib NI201100191A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0902210A FR2945210B1 (fr) 2009-05-07 2009-05-07 Combinaison antitumorale comprenant l'ave8062 et le sorafenib

Publications (1)

Publication Number Publication Date
NI201100191A true NI201100191A (es) 2012-01-16

Family

ID=41402172

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201100191A NI201100191A (es) 2009-05-07 2011-11-04 Combinación antitumoral que comprende ave8062 y sorafenib

Country Status (27)

Country Link
US (1) US20120108641A1 (es)
EP (1) EP2427185A1 (es)
JP (1) JP2012526090A (es)
KR (1) KR20120023754A (es)
CN (1) CN102438608A (es)
AR (1) AR076848A1 (es)
AU (1) AU2010244254A1 (es)
BR (1) BRPI1014197A2 (es)
CA (1) CA2761146A1 (es)
CL (1) CL2011002782A1 (es)
CO (1) CO6390102A2 (es)
CR (1) CR20110573A (es)
DO (1) DOP2011000335A (es)
EA (1) EA201171366A1 (es)
EC (1) ECSP11011440A (es)
FR (1) FR2945210B1 (es)
IL (1) IL216133A0 (es)
MA (1) MA33346B1 (es)
MX (1) MX2011011767A (es)
NI (1) NI201100191A (es)
PE (1) PE20120323A1 (es)
SG (1) SG175895A1 (es)
TN (1) TN2011000551A1 (es)
TW (1) TW201043225A (es)
UY (1) UY32618A (es)
WO (1) WO2010128259A1 (es)
ZA (1) ZA201108110B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2481404A1 (en) * 2010-11-15 2012-08-01 Sanofi An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
BR112012031917A2 (pt) * 2010-06-18 2017-11-28 Sanofi Sa combinação antitumoral compreendendo ombrabulina, um derivado de taxano e um derivado de platina
FR2968557A1 (fr) * 2010-12-09 2012-06-15 Sanofi Aventis Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab
EP3111937B1 (en) 2011-07-08 2020-06-17 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for treatment of liver cancer
FR2978662A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie
FR2978663A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cetuximab, associee a la radiotherapie
WO2015126903A1 (en) * 2014-02-18 2015-08-27 Health Research, Inc. Combination therapy for hepatocellular carcinoma
KR102272993B1 (ko) * 2019-07-09 2021-07-06 충남대학교산학협력단 퀴니딘 유도체를 유효성분으로 함유하는 항암보조제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
WO1999051246A1 (en) * 1998-04-03 1999-10-14 Ajinomoto Co., Inc. Antitumor agents
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
PT1407784E (pt) * 2001-06-25 2011-03-03 Ajinomoto Kk Agentes antitumorais
ATE529406T1 (de) * 2002-02-11 2011-11-15 Bayer Healthcare Llc Aryl-harnstoffe als kinase inhibitoren
FR2838437B1 (fr) 2002-04-11 2004-06-04 Aventis Pharma Sa Procedes de preparation de combretastatines
FR2895258B1 (fr) * 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
WO2008031835A2 (en) * 2006-09-13 2008-03-20 Novartis Ag Method of treating autoimmune diseases using vegf-pathway inhibitors

Also Published As

Publication number Publication date
ECSP11011440A (es) 2011-12-30
JP2012526090A (ja) 2012-10-25
SG175895A1 (en) 2011-12-29
WO2010128259A1 (fr) 2010-11-11
PE20120323A1 (es) 2012-04-17
CA2761146A1 (fr) 2010-11-11
BRPI1014197A2 (pt) 2016-04-26
FR2945210B1 (fr) 2011-07-01
EP2427185A1 (fr) 2012-03-14
IL216133A0 (en) 2012-01-31
TW201043225A (en) 2010-12-16
DOP2011000335A (es) 2011-12-15
KR20120023754A (ko) 2012-03-13
AU2010244254A1 (en) 2011-11-24
CL2011002782A1 (es) 2012-03-30
CO6390102A2 (es) 2012-02-29
TN2011000551A1 (fr) 2013-05-24
ZA201108110B (en) 2013-01-30
AR076848A1 (es) 2011-07-13
CN102438608A (zh) 2012-05-02
CR20110573A (es) 2011-12-08
FR2945210A1 (fr) 2010-11-12
MX2011011767A (es) 2012-02-28
EA201171366A1 (ru) 2012-05-30
MA33346B1 (fr) 2012-06-01
US20120108641A1 (en) 2012-05-03
UY32618A (es) 2010-12-31

Similar Documents

Publication Publication Date Title
NI201100191A (es) Combinación antitumoral que comprende ave8062 y sorafenib
CY1124499T1 (el) Λιπιδια για συστασεις διανομης θεραπευτικου παραγοντα
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
AR077629A1 (es) Mimetico de smac
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
UA109010C2 (en) Morpholino pyrividines and their use in therapy
GT201200126A (es) Derivados de la cromenona con actividad anti-tumoral
CR20110424A (es) Derivados de aminotetralina, composiciones farmacéuticas que los contienen, y sus usos en terapia
UA111717C2 (uk) Склад для перорального введення і ліпофільні солі метилналтрексону
MX373123B (es) Derivados deuterados de ruxolitinib.
MX338515B (es) Derivados de tetrahidroquinolina utiles como inhibidores de bromodominio.
DOP2014000008A (es) 4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk
CO6741228A2 (es) Inhibidores de la neprilisina
EA201071378A1 (ru) Дронедарон для предотвращения постоянной фибрилляции предсердий
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
JO3676B1 (ar) مركبات صيدلانية تضم فوكانات معدلة وطرق تتعلق بها
ECSP088689A (es) NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS
ECSP11011224A (es) Derivados de tiadiazoles y oxadiazoles, su preparaciòn y su aplicaciòn en terapia
AR090806A1 (es) Glucosidos de pirazol y su utilizacion en el tratamiento de la diabetes tipo i y ii
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
EA201490199A8 (ru) Терапевтические способы
MA32461B1 (fr) Dronedarone pour la prevention de cardioversion
CU20140028A7 (es) Compuesto de benzotiazolona
EA201391586A1 (ru) ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ
UA109804C2 (xx) 2-метоксипіридин-4-ільні похідні